| 1.26 -0.03 (-2.33%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.75  |
1-year : | 1.92 |
| Resists | First : | 1.5 |
Second : | 1.64 |
| Pivot price | 1.34 |
|||
| Supports | First : | 1.25 | Second : | 1.04 |
| MAs | MA(5) : | 1.28 |
MA(20) : | 1.38 |
| MA(100) : | 1.68 |
MA(250) : | 2.7 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 7.9 |
D(3) : | 8.4 |
| RSI | RSI(14): 27.3 |
|||
| 52-week | High : | 5.96 | Low : | 1.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NBP ] has closed above bottom band by 1.3%. Bollinger Bands are 60.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.31 - 1.32 | 1.32 - 1.33 |
| Low: | 1.24 - 1.25 | 1.25 - 1.26 |
| Close: | 1.25 - 1.26 | 1.26 - 1.27 |
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Sat, 17 Oct 2026
NovaBridge Biosciences stock stood at USD 1.26 on October 16, 2026, price-earnings ratio -2.2 - ad-hoc-news.de
Tue, 13 Oct 2026
Outside Greater China, NovaBridge (NBP)'s Visara gains exclusive rights to investigational eye drug VIS-102. - Stock Titan
Mon, 12 Oct 2026
3 Promising Penny Stocks With Market Caps Up To $200M - Simply Wall Street
Mon, 12 Oct 2026
NBP: NovaBridge Biosciences - Comparison to Industry - Zacks Investment Research
Wed, 30 Sep 2026
NovaBridge Biosciences (NASDAQ: NBP) Share Price, NBP Stock News, NBP Share Price & Updates - kalkine.ca
Fri, 25 Sep 2026
NBP Slides As NovaBridge Biosciences Holds Tight Range - Timothy Sykes
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 116 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 14.2 (%) |
| Held by Institutions | 34.2 (%) |
| Shares Short | 3,280 (K) |
| Shares Short P.Month | 3,580 (K) |
| EPS | -0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.73 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35 % |
| Return on Equity (ttm) | -59.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -46 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -1.83 |
| PEG Ratio | 0 |
| Price to Book value | 0.72 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|